Sign In
Buy MNPR
$60.56
-0.700 (-1.14%)
At Close: Jun 03, 2026
Geode Capital Management LLC Raises Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)
09:12am, Wednesday, 01'st Dec 2021 Dakota Financial News
Geode Capital Management LLC boosted its stake in Monopar Therapeutics Inc. (NASDAQ:MNPR) by 9.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,761 shares of the companys stock after buying an additional 2,367 shares during the period. Geode Capital Management LLCs holdings in []
Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma
08:00am, Thursday, 16'th Sep 2021
WILMETTE, Ill., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to exte
Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial
08:00am, Thursday, 05'th Aug 2021
WILMETTE, Ill., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed
Monopar Stock Gains On Launch Of Early Stage Soft Tissue Cancer Trial With Camsirubicin
09:02am, Tuesday, 03'rd Aug 2021
The FDA has signed off Monopar Therapeutics Inc's (NASDAQ: MNPR) IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced s
MNPR Stock Price Increases Over 6% Pre-Market: Why It Happened
08:23am, Tuesday, 03'rd Aug 2021
The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) increased by over 6% pre-market. This is why it happened.
Monopar Announces FDA Clearance to Proceed with Camsirubicin Clinical Trial Targeting Advanced Soft Tissue Sarcoma
08:00am, Tuesday, 03'rd Aug 2021
WILMETTE, Ill., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed
Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline Development of novel Camsirubicin analog expands Monopar's therapeutic pipeline
MNPR Stock Price: Over 3% Increase Pre-Market Explanation
08:38am, Monday, 24'th May 2021
The stock price of Monopar Therapeutics Inc (NASDAQ: MNPR) increased by over 3% pre-market. This is why it happened.
Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
04:42pm, Thursday, 13'th May 2021
First Patient Dosed in Validive ® Phase 2b/3 VOICE Clinical Trial Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021 Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer
Monopar Therapeutics Is Trading Higher On Announcing Its uPA Radiotracer Along With Pet Imaging Can Detect Breast Cancer
10:13am, Tuesday, 30'th Mar 2021
Monopar Therapeutics Inc (NASDAQ: MNPR) has announced the publication of a peer-reviewed study that demonstrated Monopar's Urokinase plasminogen activator (uPA) antibody fragment radiotracer could
MNPR Stock Price Increased Over 15% Pre-Market: Why It Happened
08:08am, Tuesday, 30'th Mar 2021
The stock price of Monopar Therapeutics Inc. (Nasdaq: MNPR) has increased by over 15% pre-market. This is why it happened.
Monopar's uPA Antibody Fragment Radiotracer Shows Potential for PET Imaging of Breast Cancer in Preclinical Study
07:30am, Tuesday, 30'th Mar 2021
WILMETTE, Ill., March 30, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designe
Monopar Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Updates
08:00am, Thursday, 25'th Mar 2021
Validive ® Phase 2b/3 VOICE Clinical Trial Commenced Camsirubicin Phase 2 Clinical Trial Anticipated to Start in Q2 2021 MNPR-101-Conjugate Data Published in European Journal of Cancer
Monopar Partners with Seasoned Medtech Executive to Explore the Potential of MNPR-101 as a uPAR Imaging Agent in Cancer Surgery
07:30am, Tuesday, 02'nd Mar 2021
- Initial focus on use in bladder cancer surgery - Initial focus on use in bladder cancer surgery
Monopar Therapeutics to Present at Upcoming Investor Conferences
07:30am, Wednesday, 24'th Feb 2021
WILMETTE, Ill., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics desi
